Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• 主要な著者: Qiao Liu (著者), Zhen Zhou (著者), Xia Luo (著者), Lidan Yi (著者), Liubao Peng (著者), Xiaomin Wan (著者), Chongqing Tan (著者), Xiaohui Zeng (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...